<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605212</url>
  </required_header>
  <id_info>
    <org_study_id>FLO-02</org_study_id>
    <secondary_id>2016-001445-61</secondary_id>
    <nct_id>NCT03605212</nct_id>
  </id_info>
  <brief_title>Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults</brief_title>
  <acronym>FLORET</acronym>
  <official_title>Open Label, Multi-centre, Parallel Group Study to Compare the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of Febuxostat Between Pediatric Patients (≥6&lt;18 Years of Age) and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the exposure of febuxostat in pediatric patients
      (≥6&lt;18 years of age) and in adults suffering from hematological malignancies at intermediate
      to high risk of TLS and to compare the effect in terms of serum uric acid levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the FLORET study it is planned to enroll 3 groups of patients in order to receive oral
      administration (film-coated tablets) of two different dose levels of febuxostat: children
      (from 6 to less than 12 years of age) will receive two different dose levels respectively;
      adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day
      respectively and adults (equal or major than 18 years of age) will receive 120 mg/day. The
      two dose levels for children and adolescents groups will be sequentially administered,
      whereas the groups that will receive the first dose levels will simultaneously start the
      treatment at the study beginning. The individual treatment duration will be of 7 to 9 days,
      according to chemotherapy duration, as per Investigator's judgement.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter: apparent clearance (CL/F)</measure>
    <time_frame>7 days</time_frame>
    <description>Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: apparent volume of distribution (Vd/F)</measure>
    <time_frame>7 days</time_frame>
    <description>Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: absorption rate constant (Ka)</measure>
    <time_frame>7 days</time_frame>
    <description>Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: area under curve (AUC)</measure>
    <time_frame>7 days</time_frame>
    <description>AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: maximum plasma concentration (Cmax)</measure>
    <time_frame>7 days</time_frame>
    <description>Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Tmax</measure>
    <time_frame>7 days</time_frame>
    <description>Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) parameter: area under the curve of serum uric acid (sUA)</measure>
    <time_frame>8 days</time_frame>
    <description>Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Laboratory Tumor Lysis Syndrome (LTLS)</measure>
    <time_frame>8 days</time_frame>
    <description>Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Tumor Lysis Syndrome (CTLS)</measure>
    <time_frame>8 days</time_frame>
    <description>Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment Emergent Signs and Symptoms (TESS)</measure>
    <time_frame>Estimated maximum time frame: 27 days</time_frame>
    <description>Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events are assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event is considered as TESS if it occurs for the first time or if it worsens in terms of seriousness or severity after first study drug intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status (PS) Evaluation</measure>
    <time_frame>Estimated maximum time frame: 27 days</time_frame>
    <description>Quality of life will be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale will be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale will be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tumor Lysis Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female children of 6 to less than 12 years of age, adolescents of 12 to less
             than 18 years of age and adults from 18 years:

          -  scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies

          -  and at intermediate or high risk of TLS

          -  and with no access to rasburicase

        Exclusion Criteria:

          -  patients with contraindications as per febuxostat summary of product characteristics

          -  patients with severe renal insufficiency

          -  patients with severe hepatic insufficiency

          -  patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Locatelli, Professor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS Ospedale Pediatrico Bambino Gesù Department of Pediatric Hematology and Oncology Piazza Sant'Onofrio, 4, 00165 Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Capriati, Corporate Director of Clinical</last_name>
    <phone>+39 055 5680</phone>
    <phone_ext>9990</phone_ext>
    <email>acapriati@menarini-ricerche.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Manunta, Clinical Research Physician</last_name>
    <phone>+39 055 5680</phone>
    <phone_ext>9520</phone_ext>
    <email>smanunta@menarini-ricerche.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tsaritsa Yoanna</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem (paediatric)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>SOC Oncologia Medica A - Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U.C. Azienda Ospedaliero - Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto G Gaslini Ospedale Pediatrico IRCCS</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TLS</keyword>
  <keyword>FLO-02</keyword>
  <keyword>Hematological Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

